- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01464281
A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml (New Switch)
A Randomized, Multicenter Study Evaluating HBsAg Clearance in CHB Patients Achieving HBeAg Loss and HBV DNA <200copies/ml on Treatment With Nucleotide Analogues and Switched to Peginterferon Alfa-2a
A Randomized, open-label, multicenter study.
The patients after 1-3 years NAs treatment and having achieved HBeAg loss and HBV DNA <200IU/ml will be switched to Pegasys for 48 or 96 weeks (with a 12 weeks period of overlap with the NA for safety reasons). The subjects will be randomized into 2 groups:
Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
All the patients will be followed up for 48 weeks after discontinuation of the study medication.
Note: NAs will be stratified LAM, ETV and ADV, with the ratio 1:1:1.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Forventet)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Chongqing
-
Chongqing, Chongqing, Kina, 400010
- The 2nd affiliated Hospital of Chongqing Medical University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients on-treatment with NAs (ADV, ETV or LAM) for 1-3 years, having achieved HBeAg loss at screening, and HBV DNA <200IU/ml for at least 48 weeks
- Male and female patients ≥ 18 to 65 years of age
- Chronic hepatitis B (positive HBsAg for at least 6 months prior to NA therapy start)
- Compensated liver disease (Child-Pugh <6)
- Absence of hepatocellular carcinoma on liver imaging and/or alfa fetoprotein < 50 ng/ml
- Negative urine or blood pregnancy test for women of childbearing potential within 24 hours of first PEG IFN study medication administration
- Able and willing to provide informed consent and abide by the requirements of the study
Exclusion Criteria:
- Neutrophil count <1.5 x 109cells/L or platelet count <90 x 109cells/L
- Co-infections with HIV, HAV, HCV, HDV or HEV
- Women with ongoing pregnancy or breast feeding, or wishing to become pregnant during the study period
- Prolonged and excessive alcohol intake (> 40g/day for men and > 30g/day for women)
- Active intravenous drug abuse
- History or current treatment with telbivudine
- Treatment with immunomodulators (e.g. Interferon) for less than one year before study enrollment
- Treatment with immunosuppressors (including systemic corticosteroids) or anti-neoplastic treatment (including radiation therapy) <=6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
- Serum concentrations of ceruloplasmin or alfa-antitrypsin consistent with an increased risk of metabolic disease
- History or other evidence of chronic pulmonary disease associated with functional limitation
- History of severe cardiac disease
- History of the severe seizure disorder or current anticonvulsivant use
- History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
- History or other evidence of severe retinopathy
- History of autoimmune disease or presence of a significant level of auto-antibodies
- Renal insufficiency (creatinine clearance of < 50 ml/min according to the Cockroft and Gault equation), kidney transplant, hemodialysis
- History of depression or uncontrolled psychiatric disorders
- Subjects protected by law or not in a position to give consent
- Patients with reproductive potential not willing to use an effective method of contraception.
- Evidence of an active or suspected cancer or a history of malignancy (other than basocellular carcinoma or in-situ cervical carcinoma)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: 48-week standard treatment
48-week standard treatment by Peginterferon alfa 2a 180µg/week
|
Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
|
Aktiv komparator: 96-week prolonged treatment
96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
|
Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
determine the response rate (HBsAg clearance at Week 48 and 96)
Tidsramme: 1 year
|
To determine the response rate (HBsAg clearance at Week 48 and 96) in subjects who are being treated by NAs and achieved a combined response which consists of both HBeAg loss and HBV DNA <1000 copies/ml
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
HBsAg/HBeAg/HBV DNA changes/ALT normalization /HBsAg seroconversion at EOT and EOF
Tidsramme: 1 year
|
|
1 year
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Hong Ren, The 2nd affiliated Hospital of Chongqing Medical University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Hu P, Shang J, Zhang WH, Gong GZ, Li YG, Chen XY, Jiang JN, Xie Q, Dou XG, Sun YT, Li YF, Liu YX, Liu GZ, Ma DW, Chi XL, Tang H, Li XO, Xie Y, Chen XP, Jiang JJ, Zha P, Hou JL, Gao ZL, Fan HM, Ding JG, Zhang DZ, Ren H. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study]. Zhonghua Gan Zang Bing Za Zhi. 2018 Oct 20;26(10):756-764. doi: 10.3760/cma.j.issn.1007-3418.2018.10.005. Chinese.
- Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018 Mar 28;6(1):25-34. doi: 10.14218/JCTH.2017.00072. Epub 2018 Mar 17.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Hepatitt, viral, menneskelig
- Hepadnaviridae-infeksjoner
- DNA-virusinfeksjoner
- Hepatitt, kronisk
- Hepatitt
- Hepatitt B
- Hepatitt B, kronisk
- Anti-infeksjonsmidler
- Antivirale midler
- Peginterferon alfa-2a
Andre studie-ID-numre
- ML27928
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kronisk hepatitt B
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Alcon ResearchFullført
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgFullførtLimbal stamcelle mangel | Hornhinnesykdom | Eyes Dry Chronic | Kronisk konjunktivitt i begge øyne | Øyelesjon | Øyesykdom; Grå stær | Øyne Tørr følelse av | Hornhinne betent | Hornhinne; Skade, slitasje | HornhinneinfeksjonØsterrike
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende diffust stort B-celle lymfom aktivert B-celletype | Refraktært diffust stort B-celle lymfom aktivert B-celletypeForente stater, Saudi-Arabia
-
Athenex, Inc.RekrutteringB-celle lymfom | CLL/SLL | ALT, barndom | DLBCL - Diffust storcellet B-celle lymfom | B-celle leukemi | NHL, tilbakefall, voksen | ALL, voksen B-celleForente stater
-
Nathan DenlingerBristol-Myers SquibbRekrutteringB-celle non-Hodgkin lymfom - tilbakevendende | Diffust stort B-celle lymfom - tilbakevendende | Follikulært lymfom - tilbakevendende | Høygradig B-celle lymfom - tilbakevendende | Primært mediastinalt stort B-celle lymfom - tilbakevendende | Transformert indolent B-celle non-Hodgkin lymfom til... og andre forholdForente stater
-
Lapo AlinariRekrutteringTilbakevendende høygradig B-celle lymfom med MYC-, BCL2- og BCL6-omorganiseringer | Refraktært høygradig B-celle lymfom med MYC, BCL2 og BCL6 omorganiseringer | Tilbakevendende høygradig B-celle lymfom med MYC og BCL2 eller BCL6 omorganiseringer | Refraktært høygradig B-celle lymfom med MYC... og andre forholdForente stater
-
Ohio State University Comprehensive Cancer CenterRekrutteringDiffust stort B-celle lymfom | Høygradig B-celle lymfom | Diffust stort B-celle lymfom, ikke spesifisert på annen måte | Diffust stort B-celle lymfom Germinalt senter B-celletypeForente stater
-
British Columbia Cancer AgencyHar ikke rekruttert ennåB-celle lymfom | Non-Hodgkins lymfom | Mantelcellelymfom | Diffust storcellet B-celle lymfom | B-celle leukemi | B-celle akutt lymfatisk leukemi | Primært mediastinalt stort B-celle lymfom (PMBCL) | Høygradig B-celle lymfomCanada
Kliniske studier på Peginterferon alfa 2a
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... og andre samarbeidspartnereUkjent
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... og andre samarbeidspartnereUkjent
-
Chugai PharmaceuticalFullført
-
Hoffmann-La RocheFullførtHepatitt B, kroniskDen russiske føderasjonen
-
Hoffmann-La RocheFullførtHepatitt B, kroniskTaiwan, Forente stater, New Zealand, Singapore
-
Hoffmann-La RocheFullførtHepatitt B, kroniskKina, Hong Kong, Australia, Tyskland, Taiwan, Singapore, Frankrike, Forente stater, Korea, Republikken, New Zealand, Thailand, Den russiske føderasjonen, Brasil
-
Beijing Ditan HospitalUkjent
-
Third Affiliated Hospital, Sun Yat-Sen UniversityFullførtAntiviral Treatment of Chronic Hepatitis B
-
M.D. Anderson Cancer CenterAvsluttet
-
Hoffmann-La RocheFullført